Preclinical
In the biotech world, only 7 to 9 percent of companies have women as their chief executives. Antiva BioSciences is a good example of how this problem is perpetuated.
Biohaven Pharma, headquartered in New Haven, Conn., announced positive data from a proof-of-concept trial for its BHV-0223 in social anxiety and public speaking anxiety disorders.
Generally speaking, the larger the animal, the more cells they have, the more likely they are to get cancer. The longer an animal lives, even if that animal is a human being, the higher the likelihood of cancer. Except elephants. Elephants rarely get cancer.
Ambys Medicines, based in Redwood City, California, has launched in an unusual deal with Osaka, Japan’s Takeda Pharmaceutical Company.
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter—basically a rejection—to Austin, Texas-based Pain Therapeutics for Remoxy ER for pain.
Navitor Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced that Thomas E. Hughes will be the company’s new chief executive officer.
Shares of Nabriva Therapeutics are rising this morning after the company announced it acquired privately-held Zavante Therapeutics.
Since taking over the helm of GlaxoSmithKline, Emma Walmsley has been driving changes at the company with a heavy focus on pharma R&D. Today, Walmsley and R&D Head Hal Barron unveiled a long-term plan for R&D that is focused on the immune system and genetics.
In April Bay Area biotech Revolution Medicines completed its pivot from a company focused on antifungal treatments to an oncology business. This morning Revolution’s shift paid off with a development deal worth up to $500 million with Sanofi.
Enzyvant Sciences, one of Vivek Ramaswamy’s numerous ‘Vant’ companies, filed a rolling submission of a Biologics License Application (BLA) for RVT-802 with the U.S. Food and Drug Administration for the treatment of DiGeorge Anomaly (cDGA), an immunodeficiency disease that impacts infants.
PRESS RELEASES